Summary of Expert Call on China's Blood Products Industry Industry Overview - The expert call focused on the blood product industry in China, particularly the dynamics surrounding albumin and intravenous immunoglobulin (IVIG) sales and inventory levels [2][7]. Key Points Inventory and Sales Dynamics - In Q425, there was a significant increase in shipments from producers, leading to higher channel inventory, particularly for albumin, where some small distributors hold over six months of inventory compared to two months for IVIG [2][8]. - The in-hospital sales volume of albumin has decreased by 30-40% following the full rollout of DRG/DIP policies in late 2025, which has tightened control over albumin prescriptions [3][8]. - The share of in-hospital sales has shifted from 60% to approximately 50%, indicating a more balanced distribution between in-hospital and ex-hospital sales channels [3][10]. Pricing Trends - In-hospital prices for albumin have fallen by about 10%, while ex-hospital prices have seen a larger decline due to intense competition [3][8]. - The in-hospital sales volume of IVIG has dropped by around 20%, but it is expected to have decent long-term growth potential due to its wide range of applications and lower per-capita use compared to overseas markets [3][11]. Plasma Collection and Industry Consolidation - Plasma collection volume has shown steady annual growth of 5-10%, although the approval process for new plasma stations remains stringent [4][16]. - The industry is expected to consolidate from over 20 companies to fewer than 10 in the long term, driven by mergers and acquisitions (M&A) as larger companies leverage advanced technology for production [4][18]. Future Outlook - The expert anticipates that the blood products industry will remain under pressure throughout 2026 due to high inventory levels and stringent control measures [2][9]. - There is a potential for a quarter-over-quarter recovery in Q226, but overall shipments are expected to be pressured year-over-year in Q126 [2][9]. Regulatory and Competitive Landscape - The rollout of value-based pricing (VBP) policies may impact albumin pricing significantly, with the possibility of tiered or region-based coverage [19]. - Domestic companies are currently stocking plasma, and while there is a possibility of import restrictions in the future, the current demand for imports remains strong [13][15]. Risks - Key risks identified for the healthcare industry include unexpected price cuts from government programs, intensified competition, and regulatory changes that could adversely affect market dynamics [20]. Additional Insights - The expert noted that while there is no efficacy difference between domestic and imported products, foreign companies have better penetration in hospitals due to established relationships [14]. - The growth trend in plasma collection is expected to continue, with leading companies potentially increasing their volume through M&A activities [16][18]. This summary encapsulates the critical insights from the expert call regarding the current state and future outlook of China's blood products industry, highlighting both opportunities and challenges.